DNA Brands, Inc.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, NNFSF has a market cap of 56.01B. Regarding current trading prices, DNAX is priced at $0.00, while NNFSF trades at $4.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas NNFSF's P/E ratio is 33.20. In terms of profitability, DNAX's ROE is +0.13%, compared to NNFSF's ROE of +0.43%. Regarding short-term risk, DNAX is less volatile compared to NNFSF. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, CCHBF has a market cap of 18.42B. Regarding current trading prices, DNAX is priced at $0.00, while CCHBF trades at $50.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas CCHBF's P/E ratio is 19.88. In terms of profitability, DNAX's ROE is +0.13%, compared to CCHBF's ROE of +0.21%. Regarding short-term risk, DNAX is less volatile compared to CCHBF. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, EMBVF has a market cap of 18.40B. Regarding current trading prices, DNAX is priced at $0.00, while EMBVF trades at $10.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas EMBVF's P/E ratio is 16.20. In terms of profitability, DNAX's ROE is +0.13%, compared to EMBVF's ROE of +0.15%. Regarding short-term risk, DNAX and EMBVF have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, CCHGY has a market cap of 17.88B. Regarding current trading prices, DNAX is priced at $0.00, while CCHGY trades at $49.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas CCHGY's P/E ratio is 19.29. In terms of profitability, DNAX's ROE is +0.13%, compared to CCHGY's ROE of +0.21%. Regarding short-term risk, DNAX is less volatile compared to CCHGY. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, ITONF has a market cap of 12.69B. Regarding current trading prices, DNAX is priced at $0.00, while ITONF trades at $61.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas ITONF's P/E ratio is 87.73. In terms of profitability, DNAX's ROE is +0.13%, compared to ITONF's ROE of +0.05%. Regarding short-term risk, DNAX is less volatile compared to ITONF. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, BTVCY has a market cap of 7.31B. Regarding current trading prices, DNAX is priced at $0.00, while BTVCY trades at $29.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas BTVCY's P/E ratio is 23.99. In terms of profitability, DNAX's ROE is +0.13%, compared to BTVCY's ROE of +0.39%. Regarding short-term risk, DNAX and BTVCY have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, YKLTY has a market cap of 6.10B. Regarding current trading prices, DNAX is priced at $0.00, while YKLTY trades at $10.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas YKLTY's P/E ratio is 17.05. In terms of profitability, DNAX's ROE is +0.13%, compared to YKLTY's ROE of +0.07%. Regarding short-term risk, DNAX is less volatile compared to YKLTY. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, YKLTF has a market cap of 6.06B. Regarding current trading prices, DNAX is priced at $0.00, while YKLTF trades at $19.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas YKLTF's P/E ratio is 16.92. In terms of profitability, DNAX's ROE is +0.13%, compared to YKLTF's ROE of +0.07%. Regarding short-term risk, DNAX and YKLTF have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, UPCHY has a market cap of 5.16B. Regarding current trading prices, DNAX is priced at $0.00, while UPCHY trades at $119.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas UPCHY's P/E ratio is 20.28. In terms of profitability, DNAX's ROE is +0.13%, compared to UPCHY's ROE of +0.14%. Regarding short-term risk, DNAX is less volatile compared to UPCHY. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, COCSF has a market cap of 4.75B. Regarding current trading prices, DNAX is priced at $0.00, while COCSF trades at $9.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas COCSF's P/E ratio is 15.60. In terms of profitability, DNAX's ROE is +0.13%, compared to COCSF's ROE of +0.17%. Regarding short-term risk, DNAX and COCSF have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, BTVCF has a market cap of 4.10B. Regarding current trading prices, DNAX is priced at $0.00, while BTVCF trades at $16.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas BTVCF's P/E ratio is 26.89. In terms of profitability, DNAX's ROE is +0.13%, compared to BTVCF's ROE of +0.39%. Regarding short-term risk, DNAX is less volatile compared to BTVCF. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, UNPSF has a market cap of 3.83B. Regarding current trading prices, DNAX is priced at $0.00, while UNPSF trades at $0.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas UNPSF's P/E ratio is 14.77. In terms of profitability, DNAX's ROE is +0.13%, compared to UNPSF's ROE of +0.14%. Regarding short-term risk, DNAX and UNPSF have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, CCOJY has a market cap of 3.00B. Regarding current trading prices, DNAX is priced at $0.00, while CCOJY trades at $8.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas CCOJY's P/E ratio is 122.86. In terms of profitability, DNAX's ROE is +0.13%, compared to CCOJY's ROE of -0.00%. Regarding short-term risk, DNAX and CCOJY have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, CCOJF has a market cap of 2.25B. Regarding current trading prices, DNAX is priced at $0.00, while CCOJF trades at $12.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas CCOJF's P/E ratio is 67.79. In terms of profitability, DNAX's ROE is +0.13%, compared to CCOJF's ROE of +0.02%. Regarding short-term risk, DNAX and CCOJF have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, ITOEF has a market cap of 2.23B. Regarding current trading prices, DNAX is priced at $0.00, while ITOEF trades at $22.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas ITOEF's P/E ratio is 30.14. In terms of profitability, DNAX's ROE is +0.13%, compared to ITOEF's ROE of +0.05%. Regarding short-term risk, DNAX and ITOEF have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, AQPW has a market cap of 2.00B. Regarding current trading prices, DNAX is priced at $0.00, while AQPW trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas AQPW's P/E ratio is -26.94. In terms of profitability, DNAX's ROE is +0.13%, compared to AQPW's ROE of -7.72%. Regarding short-term risk, DNAX is less volatile compared to AQPW. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, YNAJF has a market cap of 1.84B. Regarding current trading prices, DNAX is priced at $0.00, while YNAJF trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas YNAJF's P/E ratio is 9.11. In terms of profitability, DNAX's ROE is +0.13%, compared to YNAJF's ROE of +0.09%. Regarding short-term risk, DNAX is less volatile compared to YNAJF. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, OSOPF has a market cap of 1.41B. Regarding current trading prices, DNAX is priced at $0.00, while OSOPF trades at $0.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas OSOPF's P/E ratio is 31.57. In terms of profitability, DNAX's ROE is +0.13%, compared to OSOPF's ROE of +0.10%. Regarding short-term risk, DNAX and OSOPF have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, FQVTF has a market cap of 1.39B. Regarding current trading prices, DNAX is priced at $0.00, while FQVTF trades at $11.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas FQVTF's P/E ratio is 0.41. In terms of profitability, DNAX's ROE is +0.13%, compared to FQVTF's ROE of +0.09%. Regarding short-term risk, DNAX is less volatile compared to FQVTF. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, LSDAF has a market cap of 1.02B. Regarding current trading prices, DNAX is priced at $0.00, while LSDAF trades at $150.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas LSDAF's P/E ratio is 12.40. In terms of profitability, DNAX's ROE is +0.13%, compared to LSDAF's ROE of +0.11%. Regarding short-term risk, DNAX and LSDAF have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, BAGFF has a market cap of 734.17M. Regarding current trading prices, DNAX is priced at $0.00, while BAGFF trades at $6.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas BAGFF's P/E ratio is 18.86. In terms of profitability, DNAX's ROE is +0.13%, compared to BAGFF's ROE of +0.12%. Regarding short-term risk, DNAX and BAGFF have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, NJMVF has a market cap of 697.28M. Regarding current trading prices, DNAX is priced at $0.00, while NJMVF trades at $19.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas NJMVF's P/E ratio is 106.06. In terms of profitability, DNAX's ROE is +0.13%, compared to NJMVF's ROE of N/A. Regarding short-term risk, DNAX and NJMVF have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, HAATF has a market cap of 201.97M. Regarding current trading prices, DNAX is priced at $0.00, while HAATF trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas HAATF's P/E ratio is 12.56. In terms of profitability, DNAX's ROE is +0.13%, compared to HAATF's ROE of +0.15%. Regarding short-term risk, DNAX is less volatile compared to HAATF. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, CHFHY has a market cap of 46.85M. Regarding current trading prices, DNAX is priced at $0.00, while CHFHY trades at $6.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas CHFHY's P/E ratio is 8.48. In terms of profitability, DNAX's ROE is +0.13%, compared to CHFHY's ROE of +0.13%. Regarding short-term risk, DNAX is less volatile compared to CHFHY. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, JSDA has a market cap of 27.23M. Regarding current trading prices, DNAX is priced at $0.00, while JSDA trades at $0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas JSDA's P/E ratio is -2.61. In terms of profitability, DNAX's ROE is +0.13%, compared to JSDA's ROE of -1.89%. Regarding short-term risk, DNAX is less volatile compared to JSDA. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, KRTL has a market cap of 10.03M. Regarding current trading prices, DNAX is priced at $0.00, while KRTL trades at $0.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas KRTL's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to KRTL's ROE of +1.23%. Regarding short-term risk, DNAX is less volatile compared to KRTL. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, MOJO has a market cap of 9.20M. Regarding current trading prices, DNAX is priced at $0.00, while MOJO trades at $0.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas MOJO's P/E ratio is -12.62. In terms of profitability, DNAX's ROE is +0.13%, compared to MOJO's ROE of -2.31%. Regarding short-term risk, DNAX and MOJO have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, HIRU has a market cap of 3.69M. Regarding current trading prices, DNAX is priced at $0.00, while HIRU trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas HIRU's P/E ratio is 0.24. In terms of profitability, DNAX's ROE is +0.13%, compared to HIRU's ROE of +0.12%. Regarding short-term risk, DNAX is less volatile compared to HIRU. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, DRNK has a market cap of 3.67M. Regarding current trading prices, DNAX is priced at $0.00, while DRNK trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas DRNK's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to DRNK's ROE of -0.36%. Regarding short-term risk, DNAX and DRNK have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, FLWBF has a market cap of 3.42M. Regarding current trading prices, DNAX is priced at $0.00, while FLWBF trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas FLWBF's P/E ratio is -0.16. In terms of profitability, DNAX's ROE is +0.13%, compared to FLWBF's ROE of -0.92%. Regarding short-term risk, DNAX is less volatile compared to FLWBF. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, APRU has a market cap of 3.14M. Regarding current trading prices, DNAX is priced at $0.00, while APRU trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas APRU's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to APRU's ROE of +1.42%. Regarding short-term risk, DNAX is less volatile compared to APRU. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, FBEC has a market cap of 2.93M. Regarding current trading prices, DNAX is priced at $0.00, while FBEC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas FBEC's P/E ratio is 0.05. In terms of profitability, DNAX's ROE is +0.13%, compared to FBEC's ROE of +0.00%. Regarding short-term risk, DNAX is less volatile compared to FBEC. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, NTEI has a market cap of 2.72M. Regarding current trading prices, DNAX is priced at $0.00, while NTEI trades at $0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas NTEI's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to NTEI's ROE of -3.63%. Regarding short-term risk, DNAX and NTEI have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, RMHB has a market cap of 2.21M. Regarding current trading prices, DNAX is priced at $0.00, while RMHB trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas RMHB's P/E ratio is -0.19. In terms of profitability, DNAX's ROE is +0.13%, compared to RMHB's ROE of -1.00%. Regarding short-term risk, DNAX and RMHB have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, PLVFF has a market cap of 2.10M. Regarding current trading prices, DNAX is priced at $0.00, while PLVFF trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas PLVFF's P/E ratio is -1.50. In terms of profitability, DNAX's ROE is +0.13%, compared to PLVFF's ROE of -4.78%. Regarding short-term risk, DNAX and PLVFF have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, RVBR has a market cap of 2.09M. Regarding current trading prices, DNAX is priced at $0.00, while RVBR trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas RVBR's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to RVBR's ROE of -0.17%. Regarding short-term risk, DNAX is less volatile compared to RVBR. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, INKW has a market cap of 1.91M. Regarding current trading prices, DNAX is priced at $0.00, while INKW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas INKW's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to INKW's ROE of -0.01%. Regarding short-term risk, DNAX is less volatile compared to INKW. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, PURT has a market cap of 1.71M. Regarding current trading prices, DNAX is priced at $0.00, while PURT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas PURT's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to PURT's ROE of +0.07%. Regarding short-term risk, DNAX is less volatile compared to PURT. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, ALKM has a market cap of 864639.00. Regarding current trading prices, DNAX is priced at $0.00, while ALKM trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas ALKM's P/E ratio is -0.01. In terms of profitability, DNAX's ROE is +0.13%, compared to ALKM's ROE of -0.17%. Regarding short-term risk, DNAX and ALKM have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, HSEEF has a market cap of 739814.00. Regarding current trading prices, DNAX is priced at $0.00, while HSEEF trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas HSEEF's P/E ratio is -0.73. In terms of profitability, DNAX's ROE is +0.13%, compared to HSEEF's ROE of -19.98%. Regarding short-term risk, DNAX is less volatile compared to HSEEF. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, ASII has a market cap of 663373.00. Regarding current trading prices, DNAX is priced at $0.00, while ASII trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas ASII's P/E ratio is -0.01. In terms of profitability, DNAX's ROE is +0.13%, compared to ASII's ROE of -0.60%. Regarding short-term risk, DNAX is less volatile compared to ASII. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, FMBV has a market cap of 509782.00. Regarding current trading prices, DNAX is priced at $0.00, while FMBV trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas FMBV's P/E ratio is -0.01. In terms of profitability, DNAX's ROE is +0.13%, compared to FMBV's ROE of +0.01%. Regarding short-term risk, DNAX is less volatile compared to FMBV. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, VGID has a market cap of 378382.00. Regarding current trading prices, DNAX is priced at $0.00, while VGID trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas VGID's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to VGID's ROE of +0.00%. Regarding short-term risk, DNAX and VGID have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, HFBG has a market cap of 262614.00. Regarding current trading prices, DNAX is priced at $0.00, while HFBG trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas HFBG's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to HFBG's ROE of N/A. Regarding short-term risk, DNAX is less volatile compared to HFBG. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, KGKG has a market cap of 245331.00. Regarding current trading prices, DNAX is priced at $0.00, while KGKG trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas KGKG's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to KGKG's ROE of +0.29%. Regarding short-term risk, DNAX is less volatile compared to KGKG. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, FHBC has a market cap of 199559.00. Regarding current trading prices, DNAX is priced at $0.00, while FHBC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas FHBC's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to FHBC's ROE of +0.00%. Regarding short-term risk, DNAX is less volatile compared to FHBC. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, PDPG has a market cap of 185817.00. Regarding current trading prices, DNAX is priced at $0.00, while PDPG trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas PDPG's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to PDPG's ROE of +0.32%. Regarding short-term risk, DNAX and PDPG have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, EQLB has a market cap of 171281.00. Regarding current trading prices, DNAX is priced at $0.00, while EQLB trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas EQLB's P/E ratio is -0.40. In terms of profitability, DNAX's ROE is +0.13%, compared to EQLB's ROE of +0.16%. Regarding short-term risk, DNAX and EQLB have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, GHMP has a market cap of 155461.00. Regarding current trading prices, DNAX is priced at $0.00, while GHMP trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas GHMP's P/E ratio is -0.00. In terms of profitability, DNAX's ROE is +0.13%, compared to GHMP's ROE of +0.22%. Regarding short-term risk, DNAX and GHMP have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, MLHC has a market cap of 119956.00. Regarding current trading prices, DNAX is priced at $0.00, while MLHC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas MLHC's P/E ratio is -0.01. In terms of profitability, DNAX's ROE is +0.13%, compared to MLHC's ROE of +0.00%. Regarding short-term risk, DNAX is less volatile compared to MLHC. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, DNDT has a market cap of 119722.00. Regarding current trading prices, DNAX is priced at $0.00, while DNDT trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas DNDT's P/E ratio is -0.01. In terms of profitability, DNAX's ROE is +0.13%, compared to DNDT's ROE of +0.03%. Regarding short-term risk, DNAX and DNDT have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, TBEV has a market cap of 39715.00. Regarding current trading prices, DNAX is priced at $0.00, while TBEV trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas TBEV's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to TBEV's ROE of +1.28%. Regarding short-term risk, DNAX is less volatile compared to TBEV. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, NBVG has a market cap of 25613.00. Regarding current trading prices, DNAX is priced at $0.00, while NBVG trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas NBVG's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to NBVG's ROE of N/A. Regarding short-term risk, DNAX is less volatile compared to NBVG. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, STZU has a market cap of 22922.00. Regarding current trading prices, DNAX is priced at $0.00, while STZU trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas STZU's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to STZU's ROE of N/A. Regarding short-term risk, DNAX is less volatile compared to STZU. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, KRED has a market cap of 22637.00. Regarding current trading prices, DNAX is priced at $0.00, while KRED trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas KRED's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to KRED's ROE of +0.00%. Regarding short-term risk, DNAX and KRED have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, FGFT has a market cap of 22350.00. Regarding current trading prices, DNAX is priced at $0.00, while FGFT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas FGFT's P/E ratio is -0.00. In terms of profitability, DNAX's ROE is +0.13%, compared to FGFT's ROE of N/A. Regarding short-term risk, DNAX and FGFT have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, BVNNF has a market cap of 12326.00. Regarding current trading prices, DNAX is priced at $0.00, while BVNNF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas BVNNF's P/E ratio is -0.00. In terms of profitability, DNAX's ROE is +0.13%, compared to BVNNF's ROE of +11.24%. Regarding short-term risk, DNAX and BVNNF have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, PPBV has a market cap of 11239.00. Regarding current trading prices, DNAX is priced at $0.00, while PPBV trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas PPBV's P/E ratio is -0.01. In terms of profitability, DNAX's ROE is +0.13%, compared to PPBV's ROE of N/A. Regarding short-term risk, DNAX and PPBV have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, BGEM has a market cap of 9262.00. Regarding current trading prices, DNAX is priced at $0.00, while BGEM trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas BGEM's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to BGEM's ROE of -3.20%. Regarding short-term risk, DNAX is less volatile compared to BGEM. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, SWRI has a market cap of 1861.00. Regarding current trading prices, DNAX is priced at $0.00, while SWRI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas SWRI's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to SWRI's ROE of N/A. Regarding short-term risk, DNAX and SWRI have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, HKBV has a market cap of 1080.00. Regarding current trading prices, DNAX is priced at $0.00, while HKBV trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas HKBV's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to HKBV's ROE of N/A. Regarding short-term risk, DNAX is less volatile compared to HKBV. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, MCHA has a market cap of 505.00. Regarding current trading prices, DNAX is priced at $0.00, while MCHA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas MCHA's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to MCHA's ROE of N/A. Regarding short-term risk, DNAX and MCHA have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, BBDA has a market cap of 287.00. Regarding current trading prices, DNAX is priced at $0.00, while BBDA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas BBDA's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to BBDA's ROE of N/A. Regarding short-term risk, DNAX and BBDA have similar daily volatility (0.00).

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, AQUI has a market cap of 20.00. Regarding current trading prices, DNAX is priced at $0.00, while AQUI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas AQUI's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to AQUI's ROE of N/A. Regarding short-term risk, DNAX is less volatile compared to AQUI. This indicates potentially lower risk in terms of short-term price fluctuations for DNAX.

DNAX plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNAX stands at 1718.00. In comparison, ABVG has a market cap of 3.00. Regarding current trading prices, DNAX is priced at $0.00, while ABVG trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNAX currently has a P/E ratio of 0.01, whereas ABVG's P/E ratio is N/A. In terms of profitability, DNAX's ROE is +0.13%, compared to ABVG's ROE of +0.00%. Regarding short-term risk, DNAX and ABVG have similar daily volatility (0.00).